Composition for the prevention and treatment of kidney dysfunctions and diseases
View Patent ↗A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug comprising a combination of acetyl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.
1. A method for providing kidney protection from a kidney dysfunction caused by lithium which comprises administering to an individual in need thereof a therapeutically effective amount of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
2. A method for providing protection from a kidney dysfunction caused by lithium which comprises administering to an individual in need thereof a combination composition of a therapeutically effective amount of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
3. A method for providing protection from nephropathy caused by lithium which comprises administering to an individual in need thereof a combination composition of a therapeutically effective amount of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
4. A method for providing protection from tubular necrosis caused by lithium which comprises administering to an individual in need thereof a therapeutically effective amount of a combination composition of a therapeutically effective amount of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
5. A method for providing protection from tubular necrosis caused by lithium which comprises administering to an individual in need thereof a therapeutically effective amount of acetyl L-carnitine and propionyl L-carnitine or a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
6. A method for providing protection from tubular necrosis caused by lithium which comprises administering to an individual in need thereof 2-5 mg/kg body weight/day of acetyl L-carnitine and 2-5 mg/kg body weight/day of propionyl L-carnitine or an equimolar amount of a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
7. A method for providing protection from a kidney dysfunction caused by lithium which comprises administering to an individual in need thereof a combination composition of 2-5 mg/kg body weight/day of acetyl L-carnitine and 2-5 mg/kg body weight/day of propionyl L-carnitine or an equimolar amount of a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
8. A method for providing protection from nephropathy caused by lithium which comprises administering to an individual in need thereof a combination composition of 2-5 mg/kg body weight/day of acetyl L-carnitine and 2-5 mg/kg body weight/day of propionyl L-carnitine or an equimolar amount of a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.
9. A method for providing protection from tubular necrosis caused by lithium which comprises administering to an individual in need thereof a therapeutically effective amount of a combination composition of 2-5 mg/kg body weight/day of acetyl L-carnitine and 2-5 mg/kg body weight/day of propionyl L-carnitine or an equimolar amount of a pharmacologically acceptable salt thereof, in which the weight-ratio of acetyl L-carnitine to propionyl L-carnitine is 1:1.